How to improve the immunogenicity of chemotherapy and radiotherapy.
about
Myeloid Cells as Targets for Therapy in Solid TumorsMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyUpdate on the challenges and recent advances in cancer immunotherapyTargeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: past, present, and FuturePrimary sterile necrotic cells fail to cross-prime CD8(+) T cellsImmunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translationCancer immunotherapy via dendritic cellsTumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Current status of interleukin-10 and regulatory T-cells in cancerNZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.Immune microenvironments in solid tumors: new targets for therapy.Exploiting antitumor immunity to overcome relapse and improve remission duration.Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress.The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.TAT-RasGAP317-326-mediated tumor cell death sensitization can occur independently of Bax and Bak.Activation of dendritic cells by tumor cell death.Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies.Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapySelected anti-tumor vaccines merit a place in multimodal tumor therapies.Using immunotherapy to boost the abscopal effect.
P2860
Q26801832-9B1774EE-3D5B-4421-AFF7-741C04436EEAQ26825053-398B74DF-E046-4B93-B076-74606AB4C1F8Q27014693-6569B017-A683-4F84-913B-DCFD09D40404Q28081199-255ED2DE-C198-4395-AF58-7BC066633111Q28279623-931C7FA6-E9A3-450B-84C7-52FBD3F16FEAQ28386858-C66F2334-4FC6-4A23-8A87-DEEE7490F6D0Q29615444-067B5E37-5D61-4541-943F-56995549FC7AQ30916013-E07606A6-4286-4FD0-8F5A-8E067F75F5C3Q33732329-0E589DBB-1713-4D39-A006-7D11D89910F5Q34374026-0EE9F635-2966-491E-8F88-90105AD242DAQ35546655-A6C712A0-C252-4146-87D6-F37DCDC727D3Q35642044-5BF94C7D-A650-4ABC-A0B5-BBF63F57D285Q36044604-5795BCB8-3D7A-4704-8740-709FC690EF95Q38039442-678676E4-7335-4DC8-9859-511C8971C3EFQ38629357-D00B25DB-2AF4-4BFB-BB96-036214E4411BQ38767892-EDEC185D-122D-4030-9C58-A9BF2B52DA39Q38866745-27532BC6-39E2-4037-83B0-41A9F6218C34Q38980305-A08F95AE-A99C-439E-9796-8CE2D505AF24Q39041000-50D4098A-EE20-4ADE-97DF-F85ABC483BFAQ41274453-8A7A8A1A-053F-42CE-ADFF-273BBDB58A1CQ41826562-3653CA5C-1E69-4A34-AFED-495D77293073Q42115292-D87E7F4A-C83D-4E54-A3A6-88679C87BA7FQ42180889-1CF19116-AD49-4EA7-842F-1CA42F92D22CQ42448191-CF32F6DD-9855-453B-83D1-EA8614E7C9F6Q49958115-EE2C8FFD-5FDD-4AD7-B954-F154B9AEE210
P2860
How to improve the immunogenicity of chemotherapy and radiotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How to improve the immunogenicity of chemotherapy and radiotherapy.
@en
How to improve the immunogenicity of chemotherapy and radiotherapy.
@nl
type
label
How to improve the immunogenicity of chemotherapy and radiotherapy.
@en
How to improve the immunogenicity of chemotherapy and radiotherapy.
@nl
prefLabel
How to improve the immunogenicity of chemotherapy and radiotherapy.
@en
How to improve the immunogenicity of chemotherapy and radiotherapy.
@nl
P2860
P50
P1476
How to improve the immunogenicity of chemotherapy and radiotherapy.
@en
P2093
Rosa Conforti
P2860
P2888
P356
10.1007/S10555-011-9283-2
P577
2011-03-01T00:00:00Z